Amarin Corp. lost more than half its value in early trading after the company failed to win the backing of U.S. advisers to expand use of its fish-oil pill Vascepa for those with high levels of fat in their blood. Amarin’s American depositary receipts fell 62 percent to $1.97 at 7:52 a.m. New York time. The company had already dropped 54 percent in the 12 months through Oct. 15. Trading was halted yesterday during the advisory panel meeting.
Help employers find you! Check out all the jobs and post your resume.